SIGLEC1 and cancer: Within the first 20 days from diagnosis, LVS presented increased proportions of monocytes among circulating leukocytes (Fig. S4A, left panel), and a parallel drop in CD169-HLA-DR+ within conventional monocytes (Fig. S4A, middle panel) and in nonconventional monocytes (CD16+CD14low/-, Fig. S4A, right panel) compared to SVS, cancer controls, asymptomatic or recovered patients, as reported [23, 30].